Verzenio™ (abemaciclib) – Expanded indication
February 26, 2018 - Eli Lilly announced the FDA approval of Verzenio (abemaciclib) tablets, for use in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Top